Background: Treatment choices for heart failure vary depending on the type of heart failure and are related to the unique characteristics of each patient. The three main goals are to limit or prevent hospitalization, improve symptoms and functional capacity, and reduce mortality. Despite the latest advancements in treatment techniques for patients with heart failure with reduced ejection fraction, the prognosis remains poor and leads to harmful short- and long-term outcomes, even when symptoms improve with standard medications. Sacubitril/valsartan is a novel pharmacological therapy for heart failure with reduced ejection fraction. It is an effective medication that improves cardiac structure and function, reduces hospitalizations, and enhances the overall quality of life in patients with heart failure with reduced ejection fraction. When administered early in the course of the disease at appropriate doses, it lowers the incidence of adverse cardiovascular events and, consequently, readmission rates. Aim of Study: To evaluate the clinical outcomes following the administration of the sacubitril/valsartan combination in a sample of patients previously diagnosed with heart failure and reduced ejection fraction. Patients and Methods: This interventional trial was conducted over a seven-month period on patients with heart failure and reduced ejection fraction who were treated at one of the Cardiac Centers in Iraq. Each patient received two months of follow up. Results: There was a significant decrease in the key biomarkers related to heart failure, accompanied by an improvement in the overall clinical state. Conclusions: The use of the sacubitril/valsartan combination in Iraqi heart failure patients yielded satisfactory clinical results.